This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|September 13, 2020
AZD1222 Clinical Trials Resume in the UK
Author(s)BioPharm International Editors
Clinical trials for AZD1222 coronavirus vaccine resume in the UK as per guidance by MHRA.
Advertisement
It has been announced, in a Sept. 12, 2020 press release, that the clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, are to be resumed in the United Kingdom. Resumption of the trial follows confirmation of safety by the Medicines and Healthcare products Regulatory Agency (MHRA).
The clinical trials of AZD1222 were halted voluntarily on Sept. 6, 2020 as a result of an incidence of illness in one of the UK trial participants. A standard review process was then implemented, allowing for safety data to be analyzed by independent committees and international regulators, such as MHRA.
No further medical information has been disclosed by AstraZeneca and the University of Oxford; however, all trial investigators and participants will be updated with the relevant information. Additionally, AstraZeneca reported in the press release that all relevant information will be disclosed on global clinical registries to comply with clinical trial and regulatory standards.
Clinical trials that were taking place outside the UK are still halted until the health authorities of those countries have issued guidance that the trials can be resumed.
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5